Skip to main navigation menu Skip to main content Skip to site footer

Vol. 12 No. 5 (2013)

Articles

ANTICHOLINESTERASE AND ANTIOXIDANT ACTIVITIES OF COMMERCIAL PREPARATIONS FROM Ginkgo biloba LEAVES

Submitted: December 16, 2020
Published: 2013-10-31

Abstract

Ginkgo biloba preparations from leaves are widely used for the treatment of mild cognitive dysfunctions. This work compared thirteen commercial dietary supplements with fresh G. biloba leaves. Anticholinesterase activities and the levels of total phenolics were studied using corresponding spectrophotometric methods. Antioxidant activities were tested using ABTS and DPPH free radicals. Phenolic acids and quercetin contents were determined using HPLC-DAD. G. biloba preparations more effectively inhibited the activity of butyrylcholinesterase than acetylcholinesterase with significant (p < 0.05) differences between preparations. Selected preparations had both the highest content of total phenolics and the antioxidant activity (with ABTS and/or DPPH) whereas in the case of other samples, adverse results were obtained. Significant (p < 0.05) differences in the quercetin content were seen between individual preparations. Gallic, protocatechuic,
syringic, 4-OH-benzoic, chlorogenic, caffeic, sinapic, ferulic, 4-OH-cinnamic and o-coumaric acids were detected in studied samples. The preliminary characterization
of acetyl- and butyrylcholinesterase inhibitors from G. biloba with Sep-Pak C18 and polyvinylpolypyrrolidone revealed that these compounds are phenolics, although nonphenolics exhibiting the inhibitory activity were present in the leaves. The study aiming the purification of cholinesterase inhibitors from G. biloba is in progress.

References

Allderdice P.W., Garner H.A.R., Galtura D., Lockride O., LaDu B.N., McAalpines J., 1991. The cloned butyrylcholinesterase (BChE) gene maps to a single chromosome site. Genomics 11, 452–454.
Brand-Williams W., Cuvelier M.E., Berset C., 1995. Use of free radical method to evaluate antioxidant activity. Lebensm.-Wiss. Technol. 28, 25–30.
Deprez S., Brezillon C., Raport S., Philippe C., Mila I., Lapierre C., Scalbert A., 2000. Polymeric proanthocyanidins are catabolized by human colonic microflora into low-molecular-weight phenolic acids. J. Nutr. 130, 2733–2738.
Ellman G.L., Lourtney D.K., Andres V., Gmelin G., 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88–95.
Folin O., Ciocalteu V., 1927. On tyrosine and tryptophane determination in proteins. J. Biol. Chem. 27, 627–650.
Gawron-Gzella A., Marek P., Chanaj J., Matławska I., 2010. Camparative analysis of pharmaceuticals and dietary supplements containing extracts from the leaves of Ginkgo biloba L. Acta Pol. Pharm. 67, 335–343.
Giacobini E., 2000. Cholinesterase inhibitors: from the calabar bean to Alzheimer therapy. In: Cholinesterases and cholinesterase inhibitors, Giacobini E. (ed.). Martin Dunitz, London, 181–226.
Giacobini E., 2003. Cholinesterases: New roles in brain function and in Alzheimer Disease. Neuroch. Res. 28(3/4), 515–522.
Haan J., Hörr R., 2004. Verzögerung der progression von abhängigkeit und pflegebedürftigkeit von demenz-patienten unter behandlung mit Ginkgo-spezialextrakt Egb 761®. Wien Med. Wochenschr. 154, 511–514.
Hoyer S., Lannert H., Nöldner M., Chatterjee S.S., 1999. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (Egb 761). J. Neural. Transm. 106, 1171–1188.
Johnson S.K., Diamond B.J., Rausch, S., Kaufman, M., Shiflett, S.C., Graves, L., 2006. Ginkgo and functional measures in MS. Explore 2(1), doi:10.1016/j.explore.2005.10.007
Kang J.W., Kim J.H., Song K., Kim S.H., Yoon J.H., Kim K.S., 2010. Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3-dependent apoptosis in oral cavity cancer cells. Phytother. Res. 24, S77– S82.
Kennedy D.O., Scholey A.B., Wesnes K.A., 2000. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology 151, 416–423.
Kim K.-H., Tsao R., Yang R., Cui S.W., 2006. Phenolic acid profiles and antioxidant activities of wheat bran extracts and the effect of hydrolysis conditions. Food Chem. 95, 466–473.
Kwon S.H., Nam J.I., Kim S.H., Kim J.H., Yoon J.H., Kim K.S., 2009. Kaempferol and quercetin, essential ingredients in Ginkgo biloba extract, inhibit interleukin-1beta-induced MUC5AC gene expression in human airway epithelial cells. Phytother. Res. 23(12), 1708–1712.
Maurer K., Ihl R., Dierks T., Frölich L., 1997. Clinical efficacy of Ginkgo biloba special extract Egb761 in dementia of the Alzheimer type. J. Psychiat. Res. 31(6), 645–655.
Miller N.J., Rice-Evans C., Davies M.J., Gopinathan V., Milner A., 1993. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Cli. Sci. 84, 407–412.
Nardini M., Natella F., Scaccini C., Ghiselli A., 2006. Phenolic acids from beer are absorbed and extensively metabolized in humans. J. Nutr. Biochem. 17, 14–22.
Sabbagh M.N., Farlow M.R., Relkin N., Beach T.G., 2006. Do cholinergic therapies have diseasemodifying effects in Alzheimer’s disease? Alzheimers Dement. 2, 118–125.
Scripnikov A., Khomenko A., Napryeyenko O., 2007. Effects of Ginkgo biloba extract Egb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med. Wochenschr. 157, 295–300.
Szwajgier D., 2009. Content of individual phenolic acids in worts and beers and their possible contribution to the antiradical activity of beer. J. Inst. Brew. 115(3), 243–252.
Szwajgier D., 2012. Anticholinesterase activities of selected polyphenols. Pol. J. Food Nutr. Sci., on press
Szwajgier D., Borowiec K., 2012a. Screening for cholinesterase inhibitors in selected fruits and vegetables. EJPAU, 15(2), #06,: http://www.ejpau.media.pl
Szwajgier D., Borowiec K., 2012b. Phenolic acids from malt are efficient acetylcholinesterase and butyrylcholinesterase inhibitors. J. Inst. Brew. 118(1), 40–48.
Walesiuk A., Trofimiuk E., Braszko J.J., 2006. Ginkgo biloba normalizes stress- and corticosterone-induced impairment of recall in rats. Pharmacol. Res. 53, 123–128.
Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R., 1981. Alzheimer’s disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10, 115–126.
Young J., Wahle K.W.J., Boyle S.P., 2008. Cytoprotective effects of phenolic antioxidants and essential fatty acids in human blood monocyte and neuroblastoma cell lines: Surrogates for neurological damage in vivo. Prostag. Leukotr. Ess., 78, 45–59.

Downloads

Download data is not yet available.

Similar Articles

<< < 12 13 14 15 16 17 18 19 20 21 > >> 

You may also start an advanced similarity search for this article.